RxDoctor Payments Data

Venkateswar Nandam, MD

Internal Medicine · Orlando, FLNPI 1669444626

Payments from drug & device makers

$3,913in general payments, 2019–2025

Across 228 payments — averaging $17.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$779
  • AstraZeneca$703
  • Bayer$634
  • GSK$218
  • Amgen$186
  • Lilly USA, LLC$168
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$3,87999%
  • Education$351%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,913 in reported general payments places this provider in the 85th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$38,059
Medicare patients
109
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide246$298,363
EliquisApixaban282$273,745
JardianceEmpagliflozin187$207,057
FarxigaDapagliflozin Propanediol156$153,584
LinzessLinaclotide126$97,362
MounjaroTirzepatide65$90,482
TrulicityDulaglutide77$88,805
JanuviaSitagliptin Phosphate78$77,817
Trelegy ElliptaFluticasone/Umeclidin/Vilanter91$66,776
Tresiba Flextouch U-100Insulin Degludec74$50,103
JanumetSitagliptin Phos/Metformin Hcl39$47,545
EntrestoSacubitril/Valsartan19$30,516
SymbicortBudesonide/Formoterol Fumarate94$26,988
TradjentaLinagliptin18$25,586
Lantus SolostarInsulin Glargine,hum.Rec.Anlog185$24,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Tresiba$779$305,494262 claims
PfizerEliquis$118$273,745282 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Synjardy$103$269,180270 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$703$194,693269 claims
Lilly USA, LLCMounjaro, Trulicity$168$179,288142 claims
MerckJanuvia, Janumet, Janumet Xr$156$139,385137 claims
AbbVieLinzess$54$97,362126 claims
GSKTrelegy Ellipta, Breo Ellipta$218$89,108137 claims
NovartisEntresto$115$30,51619 claims
Astellas Pharma US IncMyrbetriq$40$24,81939 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$117$19,00471 claims
Johnson & JohnsonXarelto$140$14,98518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →